Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum94685ArticlesСтатьиReview ArticleTherapy for chronic heart failure: the possibilities of eplerenoneТерапия хронической сердечной недостаточности: возможности эплеренонаVertkinA. LВерткинА. Л

д-р мед. наук, проф., зав. каф. терапии, клинической фармакологии и скорой медицинской помощи ФГБОУ ВО «МГМСУ им. А.И.Евдокимова»

kafedrakf@mail.ruAbdullaevaA. UАбдуллаеваА. У

ассистент каф. терапии, клинической фармакологии и скорой медицинской помощи ФГБОУ ВО «МГМСУ им. А.И.Евдокимова»

kafedrakf@mail.ruKnorringG. YuКноррингГ. Ю

канд. мед. наук, доц. каф. терапии, клинической фармакологии и скорой медицинской помощи ФГБОУ ВО «МГМСУ им. А.И.Евдокимова»

knorring@mail.ruA.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian FederationФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И.Евдокимова» Минздрава России15012017191VOL 19, NO1 (2017)ТОМ 19, №1 (2017)738028122021Copyright ©; 2017, Consilium MedicumCopyright ©; 2017, ООО "Консилиум Медикум"2017Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/94685

The development of chronic heart failure (CHF) is directly associated with a high risk of adverse outcomes in patients, including such case as sudden cardiac death. Medication management in CHF is a major health and social problem. The article deals with the use of mineralocorticoid receptor antagonists (MRA) in patients with CHF. The selective MRA - eplerenone plays the main role in this treatment, because of statistically significant evidence-based data.

Развитие хронической сердечной недостаточности (ХСН) непосредственно сопряжено с высоким риском развития неблагоприятных исходов у пациентов, включая внезапную сердечную смерть. Медикаментозная коррекция ХСН представляет собой важную медицинскую и социальную проблему. Статья посвящена вопросам применения у больных с ХСН антагонистов минералокортикоидных рецепторов (МКР), в частности селективного антагониста МКР эплеренона, имеющего наиболее убедительную доказательную базу.

mineralocorticoid receptor blockersaldosteronespironolactoneeplerenonechronic heart failureблокаторы минералокортикоидных рецепторовальдостеронспиронолактонэплеренонхроническая сердечная недостаточностьGuichard J.L, Clark D3rd, Calhoun D.A, Ahmed M.I. Aldosterone receptor antagonists: current perspectives and therapies. Vasc Health Risk Manag 2013; 9: 321-31.Funder J.W. Minireview: aldosterone and mineralocorticoid receptors: past, present, and future. Endocrinol 2010; 151 (11): 5098-02.Mc Machon E. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Curr Opin Pharmacol 2001; 1 (2): 190-6.Silvestre J-S, Heymes C, Oubenaissa A et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999; 99 (20): 2694-701.Helman S.I, Liu X, Baldwin K et al. Time - dependent stimulation by aldosterone of blocker - sensitive ENaCs in A6 epithelia. Am J Physiol Cell Physiol 1998; 274 (4): C947-C957.Booth E, Johnson J.P, Stockand J.D. Aldosterone. Adv Physiol Educ 2002; 26 (1-4): 8-20.Blacher J, Amah G, Girerd X et al. Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens 1997; 10 (12): 1326-334.Brown N.J, Agirbasli M.A, Williams G.H et al. Effect of activation and inhibition of the renin - angiotensin system on plasma PAI-1. Hypertension 1998; 32 (6): 965-71.Brown N.J, Nakamura S, Ma L et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 2000; 58 (3): 1219-27.Schunkert H, Hense H.W, Muscholl M et al. Association between circulating components of the rennin - angiotensine - aldosterone system and left ventricular mass. Br Heart J 1997; 77 (1): 24-31.Mc Machon E. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Curr Opin Pharmacol 2001; 1 (2): 190-6.Верткин А.Л., Абдуллаева А.У., Шевцова В.А. Новый друг лучше старых двух. Возможности применения эплеренона в терапии хронической сердечной недостаточности. Амбулаторный прием. 2016; 2 (2): 14-23.Connell J. Aldosterone - the future challenge in cardiovascular disease? Br J Diabetes Vasc Dis 2004; 4 (6): 370-6.Duprez D, De Buyzere M, Rietzschel E.R et al. Aldosterone and vascular damage. Curr Hypertens Rep 2000; 2 (3): 327-34.Mano A, Tatsumi T, Shiraishi J et al. Aldosterone directly induces myocyte apoptosis through calcineurin - dependent pathways. Circulation 2004; 110 (3): 317-23.Rocha R, Stier C.T.Jr, Kifor I et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000; 141 (10): 3871-8.Rude M.K, Duhaney T.A.S, Kuster G et al. Aldosterone stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes. Hypertention 2005; 46 (3): 555-61.Сытник Н.В., Кокорин В.А., Люсов В.А. и др. Активность РААС и САС у больных в отдаленные сроки после первичного инфаркта миокарда. Рос. кардиол. журн. 2009; 4: 17-22.Эрлих А.Д., Грацианский Н.А. Регистр острых коронарных синдромов РЕКОРД. Характеристика больных и лечение до выписки из стационара. Кардиология. 2009; 7-8: 4-12.De Gasparo M, Joss U, Ramjoue H.P et al. Three new epoxy - spironolactone derivates: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987; 240 (2): 650-6.Delyani J, Myles K, Funder J. Eplerenone (SC 66110), a highly selective aldosteron antagonist. Am J Hypertens 1998; 11: 94AJuurlink D.N, Mamdani M.M, Lee D.S et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351 (6): 543-551.Witham M.D, Gillespie N.D, Struthers A.D. Hyperkalemia after the publication of RALES. N Engl J Med 2004; 351 (23): 2448-50.Zannad F, Gattis Stough W, Rossignol P et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J 2012; 33 (22): 2782-95.Pitt B, Zannad F, Remme W.J et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341 (10): 709-17.Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. Хроническая сердечная недостаточность. Избранные лекции по кардиологии. М.: ГЭОТАР-Медиа, 2006.Juurlink D.N, Mamdani M.M, Lee D.S et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351 (6): 543-51.Zannad F, Mc Murray J.J, Krum H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364 (1): 11-21.Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348 (14): 1309-21.Adamopoulos C, Ahmed A, Fay R et al. Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial. Eur J Heart Failure 2009; 11 (11): 1099-105.Pitt B, White H, Nicolau J et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005; 46 (3): 425-31.Денисова А.Г., Татарченко И.П., Позднякова Н.В. Структурно - геометрические показатели левого желудочка в оценке электрического ремоделирования сердца при сахарном диабете. Доктор.Ру. 2016; 11 (128): 36-41.Ryden L, Grant P.J, Anker S.D, Berne C et al. ESC guidelines on diabetes, pre - diabetes, and cadcular disease developed in collaboration with the EASD: the task force on diabetes, pre - diabetes, and cardiovascular disease of the European Society of Cardiology (ESC) and collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013; 34 (39): 3035-87.Davies J.I, Band M, Morris A, Struthers A.D. Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia 2004; 47 (10): 1687-94.Yamaji M, Tsutamoto T, Kawahara C et al. Effect of eplerenone versus spironolactone on cortisol and hemoglobin A(1) (c) levels in patients with chronic heart failure. Am Heart J 2010; 160 (5): 915-21.Joffe H.V, Kwong R.Y, Gerhard-Herman M.D et al. Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. J Clin Endocrinol Metabol 2007; 92 (7): 2552-8.Iqbal J, Parviz Y, Pitt B et al. Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure. Eur J Heart Failure 2014; 16 (2): 143-50.